Older age is a protective factor for academic achievements irrespective of treatment modalities for posterior fossa brain tumours in children.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 12 07 2020
accepted: 01 12 2020
entrez: 16 12 2020
pubmed: 17 12 2020
medline: 18 2 2021
Statut: epublish

Résumé

The treatment of children with posterior fossa brain tumours (PFBT) impacts their long term functional and imaging outcomes. This study aimed to evaluate academic achievement correlated with long-term sequelae after different PFBT treatment modalities. The study cohort consisted of 110 survivors (median age at diagnosis 10.1 years and median time of follow up 13.2 years) who completed hearing questionnaires, neurological assessment and MRI of the brain ≥5 years after the end of treatment. There were three treatment groups. A cisplatin group which underwent cisplatin chemotherapy, radiotherapy and surgery (medulloblastoma N = 40), a radiotherapy group which underwent radiotherapy and surgery (astrocytoma/ependymoma N = 30), and a surgery group (astrocytoma N = 40). Academic achievement was correlated to the age at diagnosis, ototoxicity, Karnofsky score (KS), and MRI findings (Fazekas Score (FS)- treatment related parenchymal changes). For a modelled age at diagnosis of five years, the cisplatin group had lower academic achievements compared to the radiotherapy (p = 0.028) and surgery (p = 0.014) groups. Academic achievements evaluated at a modelled age of 10 years at diagnosis did not significantly differ among the treatment groups. The cisplatin group exhibited a higher occurrence of ototoxicity than the radiotherapy (p<0.019) and surgery groups (p<0.001); however, there was no correlation between ototoxicity and academic achievements (p = 0.722) in older age at diagnosis. The radiotherapy group exhibited lower KS than the surgery group (p<0.001). KS significantly influenced academic achievements in all groups (p<0.000). The cisplatin group exhibited higher FS than the surgery group (p<0.001) while FS did not correlate with academic achievement (p = 0.399). Older age is a protective factor for academic achievements irrespective of a treatment modality.

Identifiants

pubmed: 33326475
doi: 10.1371/journal.pone.0243998
pii: PONE-D-20-21586
pmc: PMC7743944
doi:

Substances chimiques

Antineoplastic Agents 0
Cisplatin Q20Q21Q62J

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0243998

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Clin Oncol. 2016 Apr 10;34(11):1248-55
pubmed: 26811531
Magn Reson Imaging. 2006 Oct;24(8):1015-22
pubmed: 16997071
Pediatr Blood Cancer. 2012 Jun;58(6):953-8
pubmed: 21796767
Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1135-41
pubmed: 21658852
Pediatr Blood Cancer. 2016 Mar;63(3):527-34
pubmed: 26529035
J R Coll Physicians Edinb. 2017 Sep;47(3):271-275
pubmed: 29465106
J Neurooncol. 2014 Jan;116(2):387-94
pubmed: 24264531
Crit Rev Oncol Hematol. 2016 Jul;103:37-48
pubmed: 27233118
Neuroimage. 2004 Jan;21(1):261-8
pubmed: 14741664
J Clin Oncol. 1984 Mar;2(3):187-93
pubmed: 6699671
Eur J Cancer. 2009 Sep;45(14):2552-61
pubmed: 19616428
Cancer. 2015 Nov 15;121(22):4053-61
pubmed: 26287566
Neuro Oncol. 2011 Feb;13(2):223-34
pubmed: 21177781
Oncology (Williston Park). 2017 Mar 15;31(3):182-8
pubmed: 28299754
Am J Phys Med Rehabil. 2011 May;90(5 Suppl 1):S50-62
pubmed: 21765264
Childs Nerv Syst. 2011 Mar;27(3):407-13
pubmed: 20931205
J Natl Cancer Inst. 2009 Jul 1;101(13):946-58
pubmed: 19535780
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):859-66
pubmed: 19540067
Cancer. 2005 May 1;103(9):1874-80
pubmed: 15770645
Childs Nerv Syst. 2015 Oct;31(10):1877-90
pubmed: 26351237
Neuroimage. 2005 Jan 1;24(1):61-9
pubmed: 15588597
J Clin Oncol. 2006 Feb 20;24(6):884-90
pubmed: 16484697
Neurology. 2020 Aug 11;95(6):e718-e732
pubmed: 32518148
Eur J Paediatr Neurol. 2010 Mar;14(2):106-15
pubmed: 19931477
Curr Opin Pediatr. 2011 Feb;23(1):27-33
pubmed: 21157347
Strahlenther Onkol. 2017 Nov;193(11):910-920
pubmed: 28887665
Radiology. 2005 Aug;236(2):647-52
pubmed: 16040920
J Pediatr Rehabil Med. 2011;4(1):31-6
pubmed: 21757808

Auteurs

Jarmila Kruseova (J)

Department of Paediatric Haematology and Oncology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.

Anna Sarah Kovacova (AS)

Department of Radiology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.

Michal Zapotocky (M)

Department of Paediatric Haematology and Oncology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.

David Sumerauer (D)

Department of Paediatric Haematology and Oncology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.

Ivana Pernikova (I)

Department of Paediatric Neurology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.

Darja Starkova (D)

Department of Radiology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.

Adela Misove (A)

Department of Paediatric Haematology and Oncology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.

Andrea Zichova (A)

Department of Paediatric Haematology and Oncology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.

Vaclav Capek (V)

Bioinformatics Centre, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.

Thorsten Langer (T)

Pediatric Oncology and Hematology, University Hospital for Children and Adolescents, Lübeck, Germany.

Antoinette Am Zehnhoff-Dinnesen (A)

Department of Phoniatrics and Pedaudiology, University Hospital Münster, Münster, Germany.

Tomas Eckschlager (T)

Department of Paediatric Haematology and Oncology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.

Martin Kyncl (M)

Department of Radiology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH